Gaboxadol

Drug Profile

Gaboxadol

Alternative Names: Gaboxadole; LU 02-030; LU 0203; MK 0928; OV 101; THIP

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Anaesthetics; Analgesics; Anorectics; Antidepressants; Antiepileptic drugs; Hypnosedatives; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome
  • Preclinical Epilepsy; Fragile X syndrome
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 08 Sep 2016 Gaboxadol receives Orphan Drug status for Angelman syndrome in USA
  • 04 Jun 2015 Ovid Therapeutics plans phase II trials for Angelman syndrome and Fragile X syndrome
  • 20 Apr 2015 Lundbeck completes a phase I trial in Major depressive disorder in Russia and Austria (NCT00807248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top